Phase I/II Study of Ixazomib and Romidepsin in Relapsed/ Refractory Peripheral T-cell Lymphoma (PTCL)

Study on the Safety and Effectiveness of an Investigational Drug Combination for Peripheral T-cell Lymphoma

Recruiting
18 years - 100 years
All
1 Location

Brief description of study.

The purpose of this study is to test the safety and efficacy of combining two drugs, ixazomib and romidepsin. It will also measure the percentage of patients whose tumor completely resolves after receiving ixazomib and romidepsin.

Eligibility of study

You may be eligible for this study if you meet the following criteria:

  • Conditions: Peripheral T-cell Lymphoma (PTCL)
  • Age: 18 years - 100 years
  • Gender: All

Inclusion Criteria

In order to be eligible to take part in this trial, patients must meet the following criteria:

  • 18 years or older
  • Histological confirmation of peripheral T-cell lymphoma (PTCL)

For a full list of participation criteria, please visit clinicaltrials.gov.

Updated on 19 Feb 2024. Study ID: 1901200042 (BTCRC-HEM15-028)

This study investigates the safety and effectiveness of combining two investigational medications for treating peripheral T-cell lymphoma (PTCL), a type of cancer that affects the lymphatic system. The purpose is to determine how safe the combination is and how well it works in resolving tumors.

Participants in the study will receive the investigational medications and their response will be measured. The study will look at the percentage of patients whose tumors completely go away after receiving the treatment.

  • Who can participate: Adults aged 18 years or older with a confirmed diagnosis of peripheral T-cell lymphoma are eligible to participate.
  • Study details: Participants will receive the investigational combination of medications. The study will evaluate the safety and efficacy of this treatment.

Find a site

Message sent successfully.
We have submitted the information you provided to the research team at the location you chose. For your records, we have sent a copy of the message to your email address.
If you would like to be informed of other studies that may be of interest to you, you may sign up for Patient Notification Service.
Sign up

Send a message

Enter your contact details to connect with study team

Investigator Avatar

Primary Contact

First name*
Last name*
Email*
Phone number*
Preferred way of contact label
Race
Ethnicity
Other language

Default Content Message Here